AcruxASX:ACR +8.33% Net Current Asset Value is A$0.00 as of Dec. 2025. The stock has 6 warning signs investors should review. Among 946 Biotechnology companies, Acrux ranks worse than 105708.14% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Acrux's net current asset value per share for the quarter that ended in Dec. 2025 was A$0.00.
The historical rank and industry rank for Acrux's Net Current Asset Value or its related term are showing as below:
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Acrux was 7.00. The lowest was 0.79. And the median was 2.60.
ASX:ACR's Price-to-Net-Current-Asset-Value is not ranked *
in the Biotechnology industry.
Industry Median: 4.87 * Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
Acrux (ASX:ACR) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Acrux Net Current Asset Value Related Terms
Acrux Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Acrux's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:ACR vs VRTX, REGN, ALNY: Net Current Asset Value Comparison
For the Biotechnology subindustry, Acrux's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acrux Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Acrux's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Acrux's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of A$0.00 mean?
Acrux (ASX:ACR) has a Net Current Asset Value of A$0.00 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Acrux and its competitors. Over the past decade, Acrux's Net Current Asset Value has ranged from 0.79 to 7.00. According to the industry distribution chart, Acrux ranks #999999 out of 946 companies in the Biotechnology industry.
Is Acrux's Net Current Asset Value too high?
Acrux's current Net Current Asset Value is A$0.00. Over the past 10 years, this metric has ranged from a low of 0.79 to a high of 7.00. Based on the distribution chart, Acrux ranks #999999 out of 946 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Acrux's Net Current Asset Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Acrux ranks #999999 out of 946 companies for Net Current Asset Value. This places Acrux in the lower half of its industry. The industry median Net Current Asset Value is 4.87. Historically, Acrux's own Net Current Asset Value has ranged from 0.79 to 7.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.87, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Acrux and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acrux's current Net Current Asset Value is A$0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acrux stock overvalued right now?
Based on GuruFocus' analysis, Acrux (ASX:ACR) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.03, compared to a current price of A$0.01 — trading 56.7% below its estimated fair value. The current Net Current Asset Value is A$0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Acrux (ASX:ACR), the current Net Current Asset Value is A$0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Acrux Ltd is a dynamic Australian drug delivery specialist with expertise in developing and commercialising patient-preferred healthcare products for world-wide markets. Its talent creates value through the development and commercialisation of healthcare products using owned or acquired technologies. The group's products are patient preferred, protected by patent or other means, and use creative drug delivery.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ACR has been successfully added to your 